PRODUCT CODE: M1505-8

NF-κB p105/p50 Mouse Monoclonal Antibody [A2-7] (M1505-8)

Applications

  • WB

  • ICC

  • IHC-P

REACTIVITY

  • Human

  • Mouse

-
+
Western blot analysis of NF-κB p105/p50 on MCF-7 cell lysates.
  • Western blot analysis of NF-κB p105/p50 on MCF-7 cell lysates.
  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-NF-κB p105/p50 antibody. Counter stained with hematoxylin.
  • ICC staining NF-κB p105/p50 in HepG2 cells (red). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Western blot analysis of NF-κB p105/p50 on MCF-7 cell lysates.

Applications

  • WB

  • ICC

  • IHC-P

REACTIVITY

  • Human

  • Mouse

SPECIFICATIONS

Product Type

Mouse monoclonal primary

Product Name

NF-κB p105/p50 Mouse Monoclonal Antibody [A2-7] (M1505-8)

Immunogen

This antibody is produced by immunizing mice with a synthetic peptide (klh-coupled) corresponding to nf-kappab p105/p50.

Host

Mouse

Positive Control

MCF-7, HepG2, human breast carcinoma tissue

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

A2-7

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*PBS (pH7.4), 0.2% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

2 ug/ul

PURIFICATION

Protein A purified.

MOLECULAR WEIGHT

50kDa

Isotype

IgM

APPLICATION DILUTION

  • WB

  • 1:1,000-1:2,000

  • ICC

  • 1:200

  • IHC-P

  • 1:200-1:500

TARGET

UNIPROT #

PROTEIN NAME

NF-κB p105/p50

SYNONYMS

DKFZp686C01211 antibody; DNA binding factor KBF1 antibody; DNA binding factor KBF1 EBP1 antibody; DNA-binding factor KBF1 antibody; EBP 1 antibody; EBP-1 antibody; EBP1 antibody; KBF1 antibody; MGC54151 antibody; NF kappa B antibody; NF kappaB antibody; NF kappabeta antibody; NF kB1 antibody; NFkappaB antibody; NFKB 1 antibody; NFKB p105 antibody; NFKB p50 antibody; Nfkb1 antibody; NFKB1_HUMAN antibody; Nuclear factor kappa B DNA binding subunit antibody; Nuclear factor kappa-B, subunit 1 antibody; Nuclear factor NF kappa B p105 subunit antibody; Nuclear factor NF kappa B p50 subunit antibody; Nuclear factor NF-kappa-B p50 subunit antibody; Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody; p105 antibody; p50 antibody; p84/NF-kappa-B1 p98 antibody; Transcription factor NFKB1 antibody

POST-TRANSLATIONAL MODIFICATION

While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.; Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.; Polyubiquitination seems to allow p105 processing.; S-nitrosylation of Cys-61 affects DNA binding.; The covalent modification of cysteine by 15-deoxy-Delta12,14-prostaglandin-J2 is autocatalytic and reversible. It may occur as an alternative to other cysteine modifications, such as S-nitrosylation and S-palmitoylation.

SUBCELLULAR LOCATION

Nucleus. Cytoplasm.

FUNCTION

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators.